基于泰戈普拉桑的Helicobacter pylori根除三重疗法:一个III期多中心随机临床试验
Jae Yong Park1, Su Jin Hong2, Il Ju Choi3
1Division of Gastroenterology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
基于泰戈普拉桑的三重疗法在一线的Helicobacter pylori根除中显示出效率与兰索普拉相比不低. 泰戈普拉赞50mg和100mg两种疗法都能很好地耐受,并提供了可行的治疗选择.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 竞争性酸阻断剂 (P-CABs),如泰戈普拉桑,显示出强大的酸抑制效果.
- 提高Helicobacter pylori根除率是一个关键的临床目标.
研究的目的:
- 为了比较基于泰戈普拉桑的三重疗法与兰索普拉的疗效和安全性,用于一线H. pylori根除.
- 为了评估两种不同的泰戈普拉桑 (50mg和100mg) 剂量方案.
主要方法:
- 一个随机的,双盲的,主动控制的多中心试验,涉及382名先前未接受过治疗的H. pylori感染的成年人.
- 患者接受了为期14天的三重疗法,包括泰戈普拉桑 (50毫克或100毫克) 或兰索普拉佐尔,以及阿莫西西林和克拉里菌素.
- 主要终点是修改治疗意图 (mITT) 群体中的H. pylori根除率.
主要成果:
- 淘汰率为泰戈普拉桑50毫克的86.0%,泰戈普拉桑100毫克的85.5%,兰索普拉的78.7%.
- 与兰索普拉相比,泰戈普拉赞两种疗法都符合非劣质标准.
- 在克拉里思罗米辛耐药病例中,观察到泰戈普拉桑的更高的根除率,尽管在统计学上不显著. 安全概况是可比的.
结论:
- 基于泰戈普拉桑的三重疗法 (50mg和100mg) 与针对H. pylori根除的基于兰索普拉的治疗没有劣势.
- 这些疗法耐受性良好,是可行的一线治疗选择.
- 可能需要进一步研究泰戈普拉桑在抗克拉里素耐药H. pylori的疗效.
更多相关视频
05:23Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
10:44One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode
Published on: June 18, 2016
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
